<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973868</url>
  </required_header>
  <id_info>
    <org_study_id>16547</org_study_id>
    <nct_id>NCT01973868</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination</brief_title>
  <official_title>A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish safety, tolerability and pharmacokinetics of regorafenib and cetuximab in
      combination, and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose
      (RP2D)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2013</start_date>
  <completion_date type="Actual">April 3, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of regorafenib in combination with cetuximab</measure>
    <time_frame>1 month</time_frame>
    <description>MTD is defined as the maximum dose at which the incidence of dose-limiting toxicities (DLTs) during Cycle 1 is below 20 %, or as the maximum dose administered, whichever is achieved first during dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a measure of safety and tolerability</measure>
    <time_frame>Up to 2 years or longer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md (Cmax after multiple dose) for regorafenib and cetuximab</measure>
    <time_frame>Multiple time points on Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24)md (AUC from time zero to 24 hours after multiple-dose administration) for regorafenib</measure>
    <time_frame>Multiple time points on Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-26)md (AUC from time zero to 26 hours after multiple-dose administration) for cetuximab</measure>
    <time_frame>Multiple time points on Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response according to RECIST 1.1</measure>
    <time_frame>Up to 2 years or longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,md (tmax after multiple-dose administration) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab</measure>
    <time_frame>Multiple time points on Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tlast,md (tlast after multiple dosing) for regorafenib, its metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752) and cetuximab</measure>
    <time_frame>Multiple time points on Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,md for metabolites M-2 (BAY75-7495) and M-5 (BAY81-8752)</measure>
    <time_frame>Multiple time points on Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.
Subjects will receive an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.
The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.
Cetuximab infusions will be given in a once-weekly dosing-regimen as approved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (Stivarga, BAY73-4506)</intervention_name>
    <arm_group_label>Regorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab (ERBITUX)</intervention_name>
    <arm_group_label>Regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed, locally advanced or
             metastatic solid tumors who are not candidates for standard therapy or in whom
             regorafenib or cetuximab is considered a standard treatment. Patients with metastatic
             colorectal cancer (mCRC) must have a record of K-ras gene mutational analysis
             available and no K-ras mutation is present.

          -  Male or female patients ≥ 18 years of age

          -  Women of childbearing potential must have a blood or urine pregnancy test performed a
             maximum of 7 days before start of study treatment, and a negative result must be
             documented before start of study treatment

          -  Life expectancy of at least 3 months

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements conducted within 7 days of starting the study treatment:

               -  Platelet count ≥ 100,000/cubic millimeters (mm3), hemoglobin (Hb) ≥ 8.5 g/dl,
                  leukocyte count &gt; 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,000/mm3

               -  Total bilirubin ≤ 1.5 x the upper limit of normal (ULN). Mildly elevated total
                  bilirubin (&lt; 6 mg/dL) is allowed if Gilbert's syndrome is documented.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN
                  (≤ 5 x ULN for subjects with liver involvement of their cancer)

               -  Alkaline phosphatase limit ≤ 2.5 x ULN (≤ 5 x ULN for subjects whose cancer
                  involves their liver).

               -  Amylase and lipase ≤ 1.5 x ULN

               -  Serum creatinine ≤ 1.5 times ULN and creatinine clearance (CLcr) ≥ 30 mL/min
                  according to the Cockroft-Gault formula

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

        Exclusion Criteria:

          -  Prior treatment with Regorafenib

          -  Prior discontinuation of cetuximab treatment due to toxicity or intolerance of
             cetuximab

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before start of study medication

          -  Non-healing wound, ulcer, or bone fracture

          -  Systemic anticancer therapy within 28 days

          -  Patients unable to swallow and retain oral medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>October 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Regorafenib</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Cancer</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

